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Abstract
Objective—We sought to systematically review the literature on electronic nicotine delivery 
systems (ENDS, also called electronic cigarettes) awareness, use, reactions and beliefs.
Data sources—We searched five databases for articles published between 2006 and 1 July 2013 
that contained variations of the phrases ‘electronic cigarette’, ‘e-cigarette’ and ‘electronic nicotine 
delivery’.
Study selection—Of the 244 abstracts identified, we excluded articles not published in English, 
articles unrelated to ENDS, dissertation abstracts and articles without original data on prespecified 
outcomes.
Data extraction—Two reviewers coded each article for ENDS awareness, use, reactions and 
beliefs.
Data synthesis—49 studies met inclusion criteria. ENDS awareness increased from 16% to 
58% from 2009 to 2011, and use increased from 1% to 6%. The majority of users were current or 
former smokers. Many users found ENDS satisfying, and some engaged in dual use of ENDS and 
other tobacco. No longitudinal studies examined whether ENDS serve as ‘gateways’ to future 
tobacco use. Common reasons for using ENDS were quitting smoking and using a product that is 
healthier than cigarettes. Self-reported survey data and prospective trials suggest that ENDS might 
help cigarette smokers quit, but no randomised controlled trials with probability samples 
compared ENDS with other cessation tools. Some individuals used ENDS to avoid smoking 
restrictions.
Conclusions—ENDS use is expanding rapidly despite experts’ concerns about safety, dual use 
and possible ‘gateway’ effects. More research is needed on effective public health messages, 
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perceived health risks, validity of self-reports of smoking cessation and the use of different kinds 
of ENDS.
INTRODUCTION
Electronic nicotine delivery systems (ENDS), also called e-cigarettes or electronic 
cigarettes, are battery-operated devices that contain an inhalation-activated mechanism that 
heats a cartridge, producing vapour that the user, sometimes called a ‘vaper’, inhales. Liquid 
in the refillable cartridges typically has nicotine and humectants, although non-nicotine 
cartridges and disposable models are available. Notably, ENDS do not rely on combustion, 
meaning that users do not expose themselves or others to many of the harmful tobacco 
smoke constituents and particles produced by regular cigarettes.1 ENDS are controversial: 
safety information is sparse and inconsistent,23 regulation is in flux,4 and public interest is 
increasing rapidly5 despite the lack of research establishing ENDS’ long-term health effects 
or cessation properties for smokers. In addition, public health advocates are concerned that 
ENDS could act as a gateway to future smoking6 or prevent smokers from quitting by 
maintaining their nicotine addiction or deterring them from using existing, effective 
cessation tools.7 The ENDS literature is expanding rapidly, but to date no systematic review 
has summarised the findings across populations or identified gaps in the research. It is 
important to understand patterns of ENDS use across populations and time, and what beliefs 
and reactions drive either use or avoidance of ENDS. This review seeks to improve our 
understanding of who has used ENDS, how they feel about using them, and what both users 
and non-users think about this controversial product.
Safety of ENDS
With any nicotine or tobacco product, health and safety are primary public health concerns. 
However, evidence about the safety of ENDS, particularly related to the ‘e-liquid’ in the 
cartridges, is mixed. The US Food and Drug Administration (FDA) analysed the contents of 
ENDS cartridges2 and found four major tobacco-specific nitrosamines, a family of 
carcinogenic chemicals, but they reported only that these chemicals were detected, not 
whether the amounts detected reached harmful levels.8 A study of the effects of 40 different 
samples of refill liquids on pulmonary fibroblasts which model adult lung cells3 found 
tremendous variability in cytotoxicity even among individual samples from the same brand 
and flavour.
Experts disagree about the potential harms of propylene glycol, a chemical that serves as a 
humectant in e-liquid.910 While theatre fog is associated with impaired lung function,11 no 
studies have examined the long-term effects of inhaled propylene glycol in humans.7 
Ingestion of or exposure to liquid nicotine from ENDS cartridges may also be unsafe. Many 
of the cartridges and the packets of e-liquid are not childproof,12 and children might be 
drawn to the candy- and fruit-flavoured e-liquids.13 If ingested by a child, high doses of 
nicotine can be fatal.13
Another concern is the lack of quality control standards. Multiple studies have detected 
nicotine in cartridges labelled nicotine-free.21415 Some cartridges leak, are incorrectly or 
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ambiguously labelled, or vary in content even though they are labelled as being the same 
brand and flavour.312
In sum, scientific consensus has yet to emerge about the degree of danger posed by ENDS. 
Making cartridges and e-liquids childproof and instituting quality control standards would 
help avoid some safety problems. Whether purposeful exposure, that is, ongoing use of 
ENDS, has harmful long-term consequences remains an open question.
Regulation of ENDS
Approaches to regulation vary widely. For example, Brazil bans the sale, import and 
advertising of ENDS, while Finland treats ENDS as medicinal products and bans only 
advertising.16 In the USA, the FDA is expected to propose deeming regulations in fall 
2013.4 In the meantime, some local governments in the USA have taken action to prohibit 
sales to minors or otherwise restrict ENDS use.17 Given that ENDS vary widely, ranging 
from disposable models that can cost several dollars but have limited flavour and nicotine 
options to ‘personal vapourisers’ that can cost several hundred dollars but have hundreds of 
options for flavours and a wider variety of nicotine strengths, it will be important for 
policymakers to issue regulations that cover these different models.
Public interest in ENDS
The public has shown tremendous interest in ENDS, and the popular media has extensively 
covered ENDS.1819 Celebrities have used them in movies and on television.20 Between 
January 2008 and February 2010, online searches for information on ENDS increased 
several hundred-fold.5 ENDS are extensively marketed online, promoted on YouTube 
videos and advertised on Twitter.2122
One result of high levels of public interest is that ENDS have quickly become a big 
business.23–25 The current ENDS industry size is estimated to be $500 million in annual 
sales and increasing rapidly (expected to reach $1 billion by the end of 2013).232426 ‘Big 
Tobacco’ companies entered the market when Lorillard purchased Blu eCigs, a major ENDS 
brand.27 R.J. Reynolds has also introduced their own ENDS line, and Altria (owner of 
Phillip Morris USA) plans to launch MarkTen ENDS in test markets in summer 2013.25
In sum, ENDS are increasingly popular, although their safety record is not yet established 
and regulation is still in flux. There is a need to understand what the public knows and 
believes about ENDS, as well as who uses ENDS and why. Health behaviour theories and 
the empirical literature show that beliefs and attitudes drive risky behaviour, including 
health-protective behaviours like vaccination2829 and cancer screening3031 and risk-taking 
behaviours like tanning32 and unprotected sex,33 so they may also be important motivators 
of ENDS use. This review does not address product safety or biological measurements of 
ENDS as we believe a separate, indepth review would better address these critical questions. 
Thus, the goal of this review is to synthesise research on the use of and beliefs about ENDS 
in order to identify gaps in the literature, inspire future research questions and understand 
the implications of these findings for public health efforts.
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One investigator (JKP) searched PubMed, CINAHL, Web of Science, EMBASE and 
PsycInfo for articles published between 1 January 2006 (the year that ENDS became 
available in Europe and 1 year before they became available in the USA)34 and 1 July 2013. 
Search terms were: ‘electronic cigarette’ OR ‘electronic cigarettes’ OR ‘e-cigarette’ OR ‘e-
cigarettes’ OR ‘electronic nicotine delivery.’ We selected this set of broad search terms as 
no relevant medical subject heading (MeSH term) existed at the time of this review. We also 
searched the reference sections of included articles.
Study selection
After removing duplicates, both authors reviewed the titles and abstracts (k=244), and 
conference or dissertation abstracts (k=17) or articles that were not in English (k=21) were 
discarded (see figure 1). Thirteen of the non-English articles had English-language abstracts; 
two of those appeared to be relevant to the review. The additional eight articles without 
English language abstracts appeared unlikely to contain relevant information based on 
translations of their titles or visual inspection of the article (eg, they contained no numbers). 
We also excluded articles that were not relevant to ENDS, typically because the search 
query identified articles with the phrase ‘i.e. cigarettes’ (k=24). In a second step, the first 
author reviewed the remaining abstracts and, when necessary, full articles, and conferred 
with the second author where eligibility was unclear. We excluded articles that did not 
contain original data about ENDS, such as commentaries, literature reviews and information 
about regulation (k=96); experiments or laboratory studies without descriptions of ‘natural’ 
patterns of use (ie, usage not instructed by the researcher) or subjective reports from 
participants on relevant dependent variables (k=26); not peer-reviewed, such as industry 
reports (k=10); or did not include appropriate dependent variables (ie, they reported data 
about internet search engines535 or pharmacies; k=3).36 We relied on the expanded 
Campbell approach to assess study quality, focusing on factors that bear on internal validity 
(study design) and external validity (sampling).37 We did not use a quality scoring system 
that yields a single score (eg, the Jadad scale)38 because of the exceptional breadth of 
methodologies and dependent variables across the studies and because single-score 
approaches combine distinct and important issues.
Data abstraction
The first author coded the remaining articles (k=47) using a standardised data abstraction 
form. The second author or one of two additional coders reviewed each article, conferring 
with the first author in case of disagreements. Coders recorded ENDS awareness, natural 
patterns of use (ie, use outside of a lab setting, including dual use of ENDS with other 
tobacco products), subjective reactions to use (by users only), and beliefs or reasons for use 
(by users or non-users). We define ‘dual use’ as use of both ENDS and other tobacco 
products in the past 30 days. For the last two outcomes, coders also recorded whether the 
measure assessed: the perceived cost of ENDS, including the relative cost of ENDS and 
regular cigarettes (cost); the possibility that ENDS would serve as a gateway to other 
tobacco use (gateway); health, safety and side effects, including the relative safety of ENDS 
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and regular cigarettes (health); quitting or reducing smoking or tobacco use because of 
ENDS (quit); the use of ENDS to avoid restrictions on smoking (restrict); the degree of 
satisfaction with ENDS’ taste, smell and quality (satisfaction); the extent to which ENDS 
have the same taste, smell or feeling of use as regular cigarettes (similar); and changes in 
withdrawal symptoms, desire to smoke and cravings (withdrawal). For example, the 
statement ‘e-cigarettes helped me quit smoking’ would be classified as quit in the category 
of reactions, while the statement ‘I started using e-cigarettes because I wanted to be 
healthier’ would be classified as health in the category of beliefs or reasons.
We selected these codes because they represented themes that were frequently reported by 
users or were specific public health concerns. For example, we coded for restrict because 
public health advocates are worried that people will use ENDS in order to bypass existing 
smoking regulations.739 Indeed, one ENDS brand highlights this benefit in its name: 
Smoking Everywhere. We also coded for similar because, as touted by advertisements for 
the product, ENDS can look, feel or taste like regular cigarettes as a way to appeal to 
smokers who might swap regular cigarettes for electronic ones. We review perceived cost of 
ENDS as the same objective (actual) cost might be prohibitively expensive for one user but 
negligible for another.
Because of the potential for industry affiliations and funding to influence conclusions in 
tobacco research,4041 we coded that the study had a financial relationship with the ENDS 
industry if an ENDS manufacturer or distributor funded the study or supplied ENDS or 
cartridges to the researchers.
RESULTS
In all, 49 studies from 47 articles about ENDS met the inclusion criteria (see online 
supplementary table S1). The number of study participants ranged from 1 to 25 029. Of 
studies that reported location, most were conducted in the USA (k=23) or with participants 
from multiple countries (k=7). Other common locations included Italy (k=5) and the UK 
(k=4). A total of 25 studies used cross-sectional or repeated cross-sectional surveys, eight 
were laboratory experiments, five were case reports, four were observational, three were 
prospective trials, two used qualitative interviews and two used focus groups. Thirteen 
studies used probability sampling. Six studies relied on industry support; seven studies did 
not report this information. Detailed descriptions of study findings are provided in online 
supplementary appendix 1.
The studies had several important limitations. Nine studies recruited ENDS users in ways 
likely to over-represent satisfied users (eg, from online user forums, websites that sell ENDS 
or ENDS conventions42–50). It would be difficult to generalise to other populations based on 
some studies’ samples (eg, customers exiting shops in Prague;51 freshman and sophomore 
students recruited from one college lecture class;52 and YouTube videos of ENDS and 
cigarette users22). Fourteen studies did not report the date or location of data collection. 
Finally, although ENDS require some time to learn to use and models vary in quality, at 
least five laboratory studies tested only one model of ENDS or did not provide time for 
participants to learn to use the product.53–57
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ENDS awareness is generally high and increasing. In three large national surveys with 
probability sampling, awareness of ENDS among US adults increased from 16% in 200958 
to 32%–41% in 201058–60 and 58% in 2011.60 Men were more likely to be aware of ENDS 
than women in two of the three studies,5859 and younger respondents were typically more 
likely to be aware of ENDS than older respondents.58–60 In all three studies, African-
American participants were less likely to have heard of ENDS than white participants. 
Current smokers were always more likely to have heard of ENDS than never smokers and 
sometimes more likely than former smokers. For example, in a 2011 US study, 77% of 
current smokers, 65% of former smokers and 50% of never smokers had heard of ENDS.60
Studies in other countries found similar patterns of awareness. The International Tobacco 
Control (ITC) Four-Country Survey examined awareness of ENDS among probability 
samples of current and former smokers in 2010–2011 in the USA, UK, Canada and 
Australia. Across the four countries, younger, male, current smokers were more likely to 
have heard of ENDS than older, female, former smokers.61 Awareness was higher in the 
USA (73%) and UK (54%), where ENDS can be legally marketed and sold, than in Canada 
(40%) or Australia (20%), where they cannot be sold and may be more difficult to obtain.61 
In a more recent survey of UK adults, awareness varied by smoking status; 79% of daily 
smokers compared with 38% of never smokers had heard of ENDS in 2012.62
Awareness among youth was variable. Only 10% of a probability sample of middle- and 
high-school students surveyed in 2008 in Korea were aware of ENDS.63 In contrast, 86% of 
Polish students (ages 15–24)64 and 70% of Midwestern US young adults (ages 20–28)65 had 
ever heard of ENDS in separate probability-based surveys. In the latter, men, current or 
former smokers, and participants with at least one close friend who smokes, were more 
likely to be aware of ENDS than their counterparts.65 Two-thirds (67%) of US adolescent 
boys ages 11–19 had heard of ENDS when surveyed in 2011.66 The discrepancy between 
the low rates of youth awareness in Korea and the high rates in Poland and the USA may be 
due to regional differences or the dates of data collection.
In addition to the ITC Four-Country survey, two other studies examined awareness only 
among current and former smokers. More than half (58%) of US smokers were aware of 
ENDS in a large 2010 survey.59 Most (86%) of a convenience sample of adults exiting 
stores in Prague, Czech Republic, after having purchased cigarettes had heard of ENDS.51
Only three studies reported sources of awareness. The most common sources were the 
internet, friends or personal contacts, and advertisements.425063
Use of ENDS
Ever use—In large surveys, use of ENDS was low but increasing. Only 1% of US adults 
surveyed in 2009 had tried ENDS.58 Prevalence of use among the general US adult 
population was higher but still minimal (2%–3%) when assessed in 2010 in four national 
surveys with probability samples.58–6067 In all of these studies, more current smokers had 
tried ENDS than former smokers or never smokers.596067 Rates of use in the USA continued 
to rise in 2011 (6% overall) with the same gradient pattern by smoking status (1% of never 
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smokers, 7% of former smokers and 21% of current smokers).60 Demographic correlates of 
use varied across studies. When these studies limited their samples to only smokers, ENDS 
use was unrelated to history of quit attempts in two studies,5859 but smokers in one study 
who intended to quit in the next 6 months were more likely to have tried ENDS than 
smokers with no intention to quit.59
Multiple studies included only current and former smokers in their samples. Across the four 
countries surveyed by ITC, 8% of current and former smokers had ever tried ENDS.61 Daily 
heavy smokers had the highest use and long-term quitters had the lowest use. ENDS users 
were not more likely to have quit smoking since the previous wave of the ITC survey than 
non-users. Overall, 20% of adult US smokers had tried ENDS when surveyed as part of a 
2011 probability panel.68 Unsuccessful quitters were more likely to have tried ENDS than 
those who had never tried to quit. In another probability panel of US smokers, 10% of 
cigarette-only smokers had tried ENDS, but 24% of dual cigar and cigarette users had done 
so.69 Current smokers in the Legacy Longitudinal Smoker Cohort were more likely to have 
tried ENDS than former smokers (6% vs 3%, respectively).59 Li and colleagues found that 
7% of current smokers and recent quitters in New Zealand in 2011 had ever purchased 
ENDS (a proxy for use).70 Finally, in the most recent survey of ENDS use in 2012, 22% of 
current smokers in the UK had ever tried ENDS, compared with 4% of former smokers and 
<1% of never smokers.62 In many of these studies of current and former smokers, 
women6168 and younger participants5961626870 had higher rates of use than men and older 
participants. In some studies, ENDS use was not associated with quit attempts5970 or quit 
intentions.596168
In surveys with probability samples, use of ENDS by adolescents and young adults varied 
considerably by region and year, from less than 1% (US male adolescents in 2011 and 
Korean adolescents in 2008)6366 to 21% (Polish high school and university students in 
2010–2011).64 In other surveys with probability sampling, 5% of college students in North 
Carolina71 and 7% of young adults in the Midwestern US had tried ENDS.65 In general, the 
higher rate of ENDS use among Polish youth compared with US youth may relate, in part, to 
higher population-wide rates of tobacco use in Poland than in the USA.7273 Across studies 
of youth, men,63–6571 smokers63–6571 and those with important others (friends, family or 
partners) who smoked6465 were often more likely to have tried ENDS than their 
counterparts. In at least two studies, the relationship between ever use of ENDS and 
smoking status should be interpreted with caution due to the very low prevalence of 
smoking in the sample.6366
Other reported rates of ever use of ENDS are difficult to interpret because of the nature of 
their samples. For example, 85% of a convenience sample of adults surveyed by Etter and 
Bullen had used ENDS, but the majority of their participants were recruited through online 
ENDS forums.44 Among callers to seven tobacco quitlines who responded to a follow-up 
survey (35% response rate), 31% had ever tried ENDS, and users were less likely to have 
quit smoking since their initial call to the quit-line than non-users.74
Current use—Adults consistently reported low current use (ie, in the past 30 days). 
Around 1% of respondents were current ENDS users in three 2010 US national, probability-
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based surveys.585967 As with ever use of ENDS, current smokers were more likely to be 
current ENDS users than either former or never smokers.585962 In surveys limited to current 
and former smokers, rates varied from 3% (across four countries in the 2010–2011 ITC 
survey)61 to 8% (USA in 2011).68 In a convenience sample of callers to tobacco quitlines, 
9% of current and former smokers reported that they currently used ENDS some days or 
every day.74
Youth also reported low current use. Only 1% of young adults in the Midwestern USA65 and 
2% of North Carolina college students71 were current ENDS users in 2010–2011 and 2009, 
respectively. Possibly reflecting the overall higher rates of smoking in Poland compared 
with the USA, a higher percentage of high school and university students (7%) were current 
ENDS users.64
Dual use—In population-based surveys, most current (or past 30 days) smokers were not 
current (or past 30 days) ENDS users. In two 2010 probability samples of US adults, 4%59 
and 6%58 of current smokers had used ENDS in the past 30 days. More than 11% of those 
who were current users of more than one tobacco product (eg, cigarettes, cigars, snuff, 
hookah) had used ENDS in the past month.58 In another probability sample, 11% of Polish 
youth and young adults who were current smokers had used ENDS in the past 30 days.64 In 
a large survey with UK adults based on an opt-in survey panel, 3% of daily smokers in 2010 
and 7% of daily smokers in 2012 used ENDS.62
Dual use of ENDS with regular cigarettes was fairly common in convenience samples. In 
surveys with convenience samples of dedicated ENDS users, 12%–34% of ENDS users 
were current smokers.42444647 Of 179 ENDS users, 6% used hookah, snuff or some other 
non-cigarette tobacco product.47 However, among a sample of people who had bought 
ENDS 6 months earlier, 35% of current ENDS users did not smoke cigarettes, suggesting up 
to 65% dual use.48 Finally, in three prospective trials with convenience samples, dual use of 
ENDS and regular cigarettes appeared to be common, with some of the smokers who 
reduced their consumption of cigarettes continuing to use ENDS at the end of the study.75–77
Amount and duration of use—Daily use among ENDS users was common43–4755 in all 
but two studies.4874 It is difficult to further quantify the amount of use because, unlike 
regular smoking which can be measured by the number of cigarettes smoked, ENDS use has 
no clear metric. An individual does not usually ‘vape’ an entire cartridge of one ENDS in a 
single sitting. Some studies quantified use by estimating puffs per day (range 120–236),42–45 
while others reported the number of bouts of use per day (median of 20 per day46 or 67% 
use more than 15 times per day).47 Measurements of the number of e-liquid cartridges 
(range 0–4)75–77 or millilitre of e-liquid used per day (range 3–5 mL)4255 are difficult to 
interpret because cartridges leak, vary in strength both within and across brands, and require 
different levels of vacuum to inhale.31278 Another metric for quantifying use is puff 
duration. Two studies, one in a laboratory55 and one that examined 73 YouTube videos,22 
found that ENDS users take longer puffs on ENDS than conventional smokers do on regular 
tobacco cigarettes.
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Ten studies reported how long participants had been using ENDS.42–4750557479 Estimates 
varied from less than 1 month of prior use for 62% of callers to state quitlines74 to a mean of 
13 months of use in a convenience-based survey of experienced ENDS users (n=104) 
conducted in 2011.46 We are not aware of any data about the extent or amount of use of 
disposable ENDS, although five studies described the use of modified ENDS (sometimes 
called ‘mods’) or personal vapourisers that do not mimic the appearance of regular 
cigarettes.4246495079
Subjective reactions to using ENDS
Cost—ENDS users’ experiences with the cost savings from using ENDS in lieu of regular 
tobacco cigarettes are inconsistent.4350 In open-ended survey questions, some participants in 
a convenience sample survey of ENDS users (n=81) said that they found ENDS to be less 
expensive than cigarettes (10 comments), while others said they were too expensive (14 
comments).43 Most dedicated ENDS users interviewed at a convention (n=15) found them 
less expensive than cigarettes.50 Finally, among Czech smokers who had tried but stopped 
using ENDS, 13% did so because they found ENDS to be too expensive.51
Gateway use—Among the 179 Polish ENDS users surveyed online in 2009, 25 reported 
that they were non-smokers when they previously began using ENDS. Of those, 20% (n=5) 
currently smoked cigarettes at the time of the survey.47
Health and safety—Many users report positive changes in their health after they begin 
using the product. In surveys, interviews and case reports, users often describe improved 
breathing,424350 less coughing,424350 fewer sore throats,43 and improvements in overall 
health and fitness.435080 In one case report, switching from cigarettes to ENDS alleviated a 
patient’s previously elevated white blood cell count (neutrophilia).81
Some users also report experiencing side effects from using ENDS. As of the first quarter of 
2012, the FDA had received 47 reports about adverse events related to ENDS use.82 Of 
these, they classified eight as serious adverse events, including pneumonia and chest pain, 
and 39 as minor, including headache and cough. Of the 405 health effects reported by users 
in an online ENDS forum, 326 were negative; the most frequently reported problems were in 
the mouth, throat, respiratory system and neurological system.83 One case report described a 
patient developing lipid pneumonia,84 and another described a patient experiencing heart 
arrhythmia from using ENDS.85
In surveys with non-probability samples, laboratory research and other case reports, the 
majority of reported side effects were minor, including mouth or throat irritation/
dryness,42–4453 cough,478086 vertigo,4353 headache434753 and nausea.4353 In three 
prospective trials in which smokers tried ENDS for 6 or 12 months, there were no serious 
adverse events.75–77 Many of the minor side effects experienced at baseline, including 
cough,75–77 mouth and throat irritation,7577 and headache,7677 lessened considerably or 
resolved completely by the end of the study period.
Quitting or reducing tobacco use—Although successful quitting was generally not 
associated with ENDS use in large surveys,58616874 in convenience sample surveys, focus 
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groups, case studies and interviews with dedicated ENDS users, they often reported that 
using the product helped them quit smoking42–4446–50808186 or significantly reduce tobacco 
use,424448 often despite being heavy smokers or having failed quit attempts in the 
past.43444648–50808186 Unlike quitting smoking, reducing smoking may not represent a 
positive public health outcome, given that it may indicate dual use of ENDS and regular 
cigarettes.
Only three longitudinal studies have examined smokers’ use of ENDS to quit smoking. Two 
of the three prospective trials were uncontrolled. In the first, a 12-month trial with 14 
patients being treated for schizophrenia, seven of 14 participants reduced their smoking by 
at least 50% and two others quit smoking entirely.76 In the second, a 6-month prospective 
trial of 40 smokers, 13 were lost to follow-up, 13 reduced their cigarette consumption by at 
least 50% and an additional nine participants quit smoking entirely.75 Another prospective 
trial randomly assigned 300 smokers to use either ENDS with nicotine or ENDS without 
nicotine.77 At the end of the 12-month period, 11% of smokers using ENDS with nicotine 
had quit and 10% reduced their cigarette consumption by at least 50%, while 4% of the non-
nicotine group had quit and 12% had reduced their consumption. More than a third were lost 
to follow-up. The differences in cessation between groups were not statistically significant. 
The results of these trials should be interpreted with caution given that only one randomised 
participants to conditions (and it did not include a comparison condition with an alternative 
quit aid), and all three relied on convenience samples in a limited geographical setting.
Restrictions on smoking—The extent to which smokers use ENDS to avoid smoking 
restrictions was not clear. About a third (36%) of ENDS users in one survey said that they 
frequently used ENDS in places where smoking was banned.42 In contrast, in another survey 
of ENDS enthusiasts (n=104) recruited from a convention, 90% said they were able to use 
where smoking was banned, although they did not clarify how often they did so.46 In a third 
survey, a substantial number of daily ENDS users from a variety of countries reported using 
their ENDS at work (71%) or in cafes, restaurants or bars (43%), but it is difficult to 
interpret these results with respect to avoiding smoking restrictions given that they vary by 
country.44
Satisfaction—Satisfaction with ENDS that contained nicotine was moderate in most 
laboratory studies53565779 and very high in surveys of committed ENDS users.42–444950 
Users often mentioned taste and flavour. For example, more than 90% of users surveyed by 
Etter and Bullen liked the taste of ENDS.44 Smokers who used ENDS in prospective trials 
had mixed reactions7577 as did many smokers interviewed in Prauge.51 Finally, in five 
studies, ENDS users expressed concerns about the quality of ENDS they used, including 
leaking cartridges or broken components.4344505175 Some stopped using ENDS because of 
problems with the devices.4451
Similarity to regular cigarettes—Studies showed little agreement about how much 
users of ENDS thought they look, feel or taste like cigarettes, as well as whether similarity 
to cigarettes was a benefit or a drawback. In small focus groups with former smokers 
(n=11), users mentioned that they liked how using ENDS mimicked the feel of smoking 
cigarettes, and that they swapped regular cigarettes for ENDS as part of the same daily 
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routines (eg, used after a meal).49 The similarity between the products also made it easier to 
switch from one to the other. Other ENDS users recruited at a convention (n=15) noted that 
their desire for ENDS to mimic regular cigarettes had changed over time; although they 
began using ENDS that looked and felt like cigarettes, most transitioned to using personal 
vapourisers that did not look like cigarettes.50 In a large convenience sample survey, over a 
half of the participants said they used ENDS ‘in a similar manner’ as cigarettes.42 A small 
number of users stopped using ENDS because they did not have the same flavour,43 but 
others preferred the flavour of ENDS to regular cigarettes.46 During bouts of use of ENDS 
as part of lab studies (n=20 and n=32), participants’ ratings of ‘mild as own brand’5657 and 
‘taste like own brand’57 increased as they continued to use the product. In direct 
comparisons, about two-thirds of users in separate convenience sample surveys rated ENDS 
as equally or more satisfying than cigarettes.4247
Withdrawal symptoms, desire to smoke and cravings—ENDS typically provided 
some relief of smokers’ nicotine cravings and withdrawal symptoms. In six lab studies, 
participants who had been tobacco abstinent for 2–12 h reported that using nicotine-
containing ENDS reduced their desire to smoke or cravings during their inlaboratory use 
session,535657798788 although this was not true in one study.54 In some cases, this reduction 
was shown to be greater for nicotine-containing ENDS than for non-nicotine ENDS538788 or 
for just holding unlit regular cigarettes or ENDS.5688 Interestingly, this reduction in desire to 
smoke or lessening of cravings occurred even in some cases where objectively measured 
nicotine uptake was low or modest.5356 Evidence for the alleviation of specific withdrawal 
symptoms in these lab studies was inconsistent.535657798788
Dedicated ENDS users frequently reported that using ENDS successfully reduced their 
cravings to smoke and some withdrawal symptoms.42–44464950 For example, experienced 
vapers interviewed at the Midwest Vapefest ‘routinely described relief of nicotine cravings 
within 5 minutes of vaping’ and said they could comfortably go long periods of time 
between bouts of use without experiencing withdrawal symptoms.50 However, in a large 
online survey with current and former users, 33% of users said they stopped using because 
ENDS did not reduce their cravings.44 Finally, in the three prospective trials in Italy that 
followed smokers who began using ENDS for 6–12 months, participants experienced few or 
no withdrawal symptoms.75–77
Beliefs about and reasons for using ENDS
Cost—ENDS users’ beliefs about the cost savings from using ENDS in lieu of regular 
tobacco cigarettes are inconsistent. In multiple convenience sample surveys from the USA 
and other countries, a small per cent of users said they first tried or used ENDS for cost 
savings,42434774 although a much higher per cent reported this reason in another 
convenience sample survey.44 More than half (53%) of UK smokers, including a mix of 
users and non-users, believed that ENDS might be too expensive.62
Gateway use—One study documented beliefs about ENDS as gateways to use of tobacco 
products. Young adult smokers and non-smokers in focus groups in Minnesota, USA, 
believed that ENDS and other novel tobacco products, including snus and dissolvable 
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tobacco, might appeal to non-smokers who have ‘always wanted to know the feeling of a 
cigarette’.89 They felt that these products could lead non-smokers to become smokers.
Health and safety—Many users believe that ENDS are healthier than regular cigarettes 
for themselves42–4446474950 or for others,46 and they use ENDS for this reason. For example, 
of 179 Polish adult ENDS users in a convenience sample, 82% believed that ENDS were 
less dangerous than cigarettes, and an additional 15% believed that ENDS were ‘absolutely 
safe’.47 Typically, only a handful of users are concerned about the potential negative health 
effects or toxicity of ENDS.4344
Respondents in surveys that include non-users generally indicate slightly less confidence in 
the healthfulness of ENDS. In three probability sample surveys of adult current and former 
smokers, 70%–85% of those who were aware of ENDS believed they were less harmful than 
regular cigarettes.5961 In a non-probability survey of adult smokers in the UK, 71% held this 
belief, although 21% still felt that ENDS might not be safe enough.62 Only a third of adult 
New Zealand smokers believed that ENDS were less harmful than regular cigarettes.70
In multiple studies of students and young adults, 23%–55% believed that ENDS were safer 
than regular cigarettes.646571 In focus groups, young adults who had never tried ENDS 
expressed mixed beliefs about whether ENDS were equivalent to or less harmful than 
regular cigarettes.89
Examining Twitter accounts related to smoking cessation, Prochaska and colleagues also 
found a range of beliefs about the healthfulness of ENDS, including tweets with health 
warnings as well as tweets touting health benefits.90
Quitting or reducing tobacco use—The majority of ENDS users believe that ENDS 
can help people quit or reduce smoking, and they often use ENDS themselves for this 
reason.42–4446474961627480 Two surveys with probability sampling described beliefs about 
the cessation properties of ENDS. Among Midwestern young adults (ages 20–28), almost 
half (45%) of those who had heard of ENDS agreed that they can help people quit 
smoking.65 A third of New Zealand smokers believed that ENDS could help smokers quit, 
and 58% said they would be willing to try ENDS for that reason.70
In two studies in which researchers provided smokers with ENDS (both n=40), these 
smokers later said that they would recommend ENDS to friends or family who wished to 
quit smoking.5375 Some commercial and personal Twitter accounts also promoted ENDS as 
a quit tool.90 Finally, in focus groups of young adult non-users (n=66), participants 
expressed differing opinions about whether ENDS could be used as a cessation device, and 
some spontaneously recounted anecdotes about people they knew who quit smoking using 
ENDS.89
Restrictions on smoking—ENDS users have conflicting beliefs about using ENDS to 
avoid smoking restrictions. In some surveys, only a small per cent of users describe this as a 
motivation.42434774 However, in other surveys, more than 40% of respondents said they 
used ENDS for this reason.466162
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In small focus groups, non-users noted that an advantage of ENDS and other novel tobacco 
products (snus, dissolvable tobacco) is the ability to get around smoking bans and use them 
in places where one cannot smoke.89
Satisfaction—Some vapers use ENDS for the pleasure of the experience.43 Smokers who 
have not tried ENDS had mixed opinions about their potential satisfaction. About one third 
believed that ENDS might taste unpleasant.62
Similarity to regular cigarettes—Some smokers and users liked that ENDS resembled 
or felt like regular cigarettes, while others considered this a drawback.42436274 Certain 
elements of the vaping and smoking experiences were clearly different. Because ENDS are 
more complex than cigarettes, interviewed users (n=15) noted that, unlike cigarettes, they 
required a learning curve to use properly.50 In focus groups, some young adult smokers 
mentioned that the social experience of smoking might not be replicated with ENDS.89
Withdrawal symptoms, desire to smoke and cravings—Beliefs about the addictive 
properties of ENDS vary. About a quarter of Midwestern young adults, most of whom were 
non-users, believed that ENDS are less addictive than regular cigarettes.65 In contrast, in an 
internet-based survey of a convenience sample of Polish ENDS users, 60% believed that 
ENDS were less addictive than regular cigarettes, and an additional 7% believed that ENDS 
were not addictive at all.47 However, more than a half believed they were addicted to ENDS.
Very few (8%) ever users in another online survey said they were afraid of becoming 
addicted to ENDS, although 4% of the sample stated that they used ENDS because they 
were unable to stop using them.44 More than half (60%) of UK smokers, only some of 
whom had used ENDS, believed that ENDS might satisfy the desire to smoke.62 Indeed, 
some vapers used ENDS to relieve their cravings or alleviate their withdrawal 
symptoms.4344465074
Other beliefs—Three other important themes emerged in the literature. First, concerns 
about personal appearance (eg, preventing yellow teeth) or odour (eg, clothes not smelling 
like smoke) sometimes motivated interest in or use of ENDS.4344474950627589 Second, 
ENDS users felt a sense of camaraderie with one another; they gathered at vaping 
conventions4650 and in online forums where they shared information, recommendations and 
personal experiences.434950 However, a small minority of ENDS users were concerned 
about the social acceptability of ENDS use and felt embarrassed about using the 
product.4251 University students, few of whom had tried ENDS, viewed ENDS use as more 
socially acceptable than smoking.52 Third, some ENDS enthusiasts were concerned that the 
product will be banned.434450 We did not find any arguments by users that ENDS should be 
specifically exempted from smoke-free indoor air laws.
CONCLUSIONS
As the public health community settles an internal debate over the safety and cessation 
properties of ENDS, interest and use by the public are increasing rapidly. Consistently 
across the literature, current and former smokers were more likely to be aware of and use 
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ENDS than non-smokers, although quit intentions and attempts were often not associated 
with ENDS use. In surveys and interviews with dedicated ENDS users, users were generally 
satisfied with the product and believed it was healthier than regular cigarettes. Current and 
former smokers believed that ENDS could help them quit smoking, and a significant 
proportion reported that ENDS already helped them reduce the amount they smoke or quit 
entirely. Dedicated ENDS users who are or were smokers often commented that ENDS 
alleviate their cravings to smoke, and they felt healthier because of using ENDS. Some 
evidence suggested that smokers use ENDS in order to avoid smoking restrictions, but no 
longitudinal studies have evaluated whether ENDS serve as a gateway to future tobacco use. 
In lab-based studies, smokers often reported that ENDS reduced their desire to smoke and 
alleviated some withdrawal symptoms, although they experienced minor side effects. In 
prospective trials testing ENDS as a potential quit aid, a moderate number of smokers were 
able to quit, but many appeared to engage in dual use of ENDS and regular cigarettes.
Some of the reviewed studies received either funding from ENDS companies or used ENDS 
that these companies donated. Prior systematic reviews have found that financial 
relationships may influence study findings. For example, nearly all studies funded by the 
tobacco industry found a relationship between smoke-free restaurant and bar laws and 
reduced sales or employment in the hospitality industry; none of the non-industry supported 
studies found this association.40 Although we detected no apparent pattern of results 
associated with ENDS industry funding, it remains important to be aware of possible 
conflicts of interest when interpreting these findings.
The literature on ENDS described in this review suggests several important questions that 
future research should address. First, future research should identify effective messages for 
discouraging ENDS use among vulnerable populations, given the beliefs and attitudes 
identified in our review. Two specific vulnerable populations are non-smokers who could 
begin smoking as a result of developing nicotine addiction from ENDS use and smokers 
who use ENDS only as a bridge to their next cigarette. If we better understand why ENDS 
may be attractive to some vulnerable populations (eg, teenagers think ENDS are 
fashionable),89 we can craft and deliver effective messages that deter use.
Another question for future research is how well perceived health risks of using ENDS 
correspond to objective risks, and whether beliefs about these risks change as additional 
safety data become available. Future safety studies will hopefully clarify some of the 
conflicting findings of past studies.239 Current ENDS users who are former smokers 
frequently state that they use ENDS because they are healthier than regular cigarettes. If 
future safety studies find evidence of long-term harms, will these ENDS users stop using? If 
not, can we improve how we communicate safety information? Designing appropriate 
warning labels on ENDS packages could be an important first step.
A third important research question is whether ENDS users’ self-reports of successful 
smoking cessation match evidence from the currently ongoing randomised controlled trials 
(RCTs) evaluating the efficacy of ENDS as a smoking cessation tool. Caponnetto and 
colleagues conducted an RCT, but it did not include an arm testing an alternative to ENDS 
(ie, nicotine replacement therapies (NRTs) or other proven smoking cessation methods).77 
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Bullen and colleagues recently described the protocol for their study in which adult smokers 
who want to quit are randomly assigned to use ENDS with 16 mg nicotine cartridges, 21 mg 
nicotine patches or placebo (ENDS with 0 mg nicotine).91 The primary outcome is the 
proportion of participants who maintain smoking abstinence 6 months after the start of the 
study, but investigators will also assess reductions in smoking, safety of the ENDS and 
patches, and perceptions of the products. This RCT and other similar studies are critical to 
understanding whether, as users have reported, ENDS can serve as harm reduction tools.
Finally, it will be important to understand how users of the various kinds of ENDS differ. 
ENDS are available in many different varieties. For example, there are disposable ENDS, 
often available at gas stations for only a few dollars, and more expensive refillable models 
that require an initial investment for a starter kit. Some ENDS mimic the appearance of 
regular cigarettes, while some modified ENDS do not resemble cigarettes. Understanding 
whether and why different types of ENDS appeal to different populations could assist efforts 
to regulate these products. For example, if young people who have not already initiated 
tobacco use prefer inexpensive, readily available disposable models, restricting the sale of 
these models would be a key public health priority.
Several additional research questions, beyond the scope of the material covered in this 
review, will also be important to answer. One key question is whether ENDS are safe to use. 
Observing adverse events in RCTs, such as the one described by Bullen and colleagues,91 
will help to determine this. What is the best way to measure ENDS use (eg, number of puffs 
vs number of e-liquid cartridges used) so that findings can be compared across studies? Do 
ENDS act as gateway devices, causing individuals who would not otherwise use tobacco to 
initiate use? More than 10% of college students who reported using ENDS had never 
smoked a conventional cigarette,71 and we do not yet know whether these young people will 
start smoking as a result of their experience with ENDS. Prospective cohort studies, 
particularly with adolescents and young adults, are necessary to track patterns of use of 
ENDS and other tobacco products. Other important questions posed by a recent Cancer 
Research UK report include: how will future regulation impact quit attempts using ENDS; 
do ENDS ‘re-normalise’ smoking; and are ENDS undermining the use of other NRTs in 
smoking cessation attempts?16
Limitations to this systematic review include that, because the quality of the studies included 
in this review varies tremendously, readers should interpret the findings with care. In 
addition, as we reviewed only articles written in English and indexed electronically or cited 
in papers we reviewed, the review may have missed some relevant articles. While we 
provide an overview of findings across the literature, we did not conduct a meta-analysis to 
provide a quantitative synthesis due to the small number of studies and variability in their 
designs and measures. Also, the codes we developed may not have included all relevant 
areas and some findings may have overlapped across codes. Finally, because this literature is 
young and evolving quickly, the conclusions of this review may not capture all of these 
changes.
In sum, concerns about ENDS include their safety, lack of regulation, possibility of gateway 
use, and potential for dual use or avoidance of existing smoking restrictions. However, harm 
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reduction advocates note that ENDS may be less harmful—and are highly unlikely to be 
more harmful—to smokers than regular cigarettes which are a proven cause of morbidity 
and mortality.892 Thus, the concerns about ENDS must be balanced with the possibility that 
ENDS could prove to be a valuable harm reduction tool for addicted adult smokers, 
provided they do not encourage dual use or prevent other cessation efforts. Furthermore, as 
we learn more about the safety of ENDS and their efficacy as a quit tool, we will hopefully 
be able to design better tobacco control and cessation programmes in the future.
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What this paper adds
Electronic nicotine delivery systems (ENDS) could be a harm-reducing alternative to 
regular cigarettes among adult tobacco smokers, but they could also be used to avoid 
smoking restrictions or act as a gateway to other tobacco use. This systematic review 
found that:
• ENDS awareness and use are increasing.
• Users frequently report improved health and a high degree of satisfaction with 
the product.
• Many users say that ENDS helped them quit smoking, but this claim has not yet 
been evaluated by randomised controlled trials comparing ENDS with other 
cessation tools.
Future research should examine whether perceptions of ENDS’ safety change as more 
objective safety data become available, what public health messages are best for 
discouraging use among vulnerable populations and whether different types of ENDS 
(eg, disposable vs refillable) attract different user populations.
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Flow diagram of literature search and article identification.
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